ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor ModelsCherrie K. Donawho, David J. Frost, Thomas D. Penning et al.|Clinical Cancer Research|2007Cited by 770
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug ConjugateAndrew C. Phillips, Edward B. Reilly, Martin J. Voorbach et al.|Molecular Cancer Therapeutics|2018Cited by 52